Conivaptan and its role in the treatment of hyponatremia.

Article Details

Citation Copy to clipboard

Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD

Conivaptan and its role in the treatment of hyponatremia.

Drug Des Devel Ther. 2009 Dec 29;3:253-68.

PubMed ID

20054444 [ View in PubMed

]

Abstract

Hyponatremia is the most common electrolyte abnormality in hospitalized patients and is associated with increased morbidity and mortality. The recognition of the central role that arginin vasopressin plays in the pathogenesis of hyponatremia and the discovery that its actions are mediated by stimulation of V(1A) and V(2) receptors have led to the development of a new class of drugs, the arginin vasopressin antagonists. Conivaptan is a nonselective V(1A) and V(2) receptors antagonist that was the first of this class to be approved by the FDA for the management of euvolemic and hypervolemic hyponatremia. Its short-term safety and efficacy for the correction of hyponatremia have been established by multiple double-blind, randomized, controlled studies. Blocking the effects of arginin vasopressin on V(2) receptors produces aquaresis--the electrolyte-sparing excretion of water--an ideal approach to correct hypervolemic hyponatremia. The nonselectivity of conivaptan offers a theoretical advantage for its use in heart failure that may merit further exploration.

DrugBank Data that Cites this Article

Drugs

Conivaptan

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Conivaptan	Vasopressin V1a receptor	Protein	Humans	Yes	Antagonist	Details
Conivaptan	Vasopressin V2 receptor	Protein	Humans	Yes	Antagonist	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software